Protagonist Pretax Profit Margin from 2010 to 2024

PTGX Stock  USD 41.65  1.00  2.46%   
Protagonist Therapeutics Pretax Profit Margin yearly trend continues to be fairly stable with very little volatility. Pretax Profit Margin will likely drop to -1.38 in 2024. During the period from 2010 to 2024, Protagonist Therapeutics Pretax Profit Margin regression line of annual values had significance of  0.65 and arithmetic mean of (24.50). View All Fundamentals
 
Pretax Profit Margin  
First Reported
2010-12-31
Previous Quarter
(1.32)
Current Value
(1.38)
Quarterly Volatility
86.49418065
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Protagonist Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Protagonist Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 3.5 M, Interest Expense of 4.1 M or Selling General Administrative of 18 M, as well as many indicators such as Price To Sales Ratio of 20.61, Dividend Yield of 0.0 or PTB Ratio of 4.06. Protagonist financial statements analysis is a perfect complement when working with Protagonist Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Protagonist Therapeutics Correlation against competitors.
For more information on how to buy Protagonist Stock please use our How to Invest in Protagonist Therapeutics guide.

Latest Protagonist Therapeutics' Pretax Profit Margin Growth Pattern

Below is the plot of the Pretax Profit Margin of Protagonist Therapeutics over the last few years. It is Protagonist Therapeutics' Pretax Profit Margin historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Protagonist Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Pretax Profit Margin10 Years Trend
Pretty Stable
   Pretax Profit Margin   
       Timeline  

Protagonist Pretax Profit Margin Regression Statistics

Arithmetic Mean(24.50)
Coefficient Of Variation(353.04)
Mean Deviation41.68
Median(1.84)
Standard Deviation86.49
Sample Variance7,481
Range336
R-Value(0.13)
Mean Square Error7,926
R-Squared0.02
Significance0.65
Slope(2.47)
Total Sum of Squares104,737

Protagonist Pretax Profit Margin History

2024 -1.38
2023 -1.32
2022 -4.79
2021 -4.59
2020 -2.27
2019 -337.13
2018 -1.28

About Protagonist Therapeutics Financial Statements

Protagonist Therapeutics investors use historical fundamental indicators, such as Protagonist Therapeutics' Pretax Profit Margin, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Protagonist Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Pretax Profit Margin(1.32)(1.38)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Protagonist Stock Analysis

When running Protagonist Therapeutics' price analysis, check to measure Protagonist Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protagonist Therapeutics is operating at the current time. Most of Protagonist Therapeutics' value examination focuses on studying past and present price action to predict the probability of Protagonist Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protagonist Therapeutics' price. Additionally, you may evaluate how the addition of Protagonist Therapeutics to your portfolios can decrease your overall portfolio volatility.